Andrew Feldhaus Email

VP Preclinical Development . Icosavax

Current Roles

Employees:
66
Revenue:
$7.3M
About
Icosavax is focused on developing safe and effective vaccines against infectious diseases that address important unmet medical needs and reduce healthcare costs. The company was founded on breakthrough computationally-designed virus like particle technology, exclusively licensed for a variety of infectious disease indications from the Institute for Protein Design at the University of Washington. Icosavax is located in Seattle.
Icosavax Address
1616 Eastlake Avenue E.
Seattle, WA
United States

Past Companies

Icosavax, Inc.Vice President Preclinical Development
Icosavax, Inc.Senior Director Preclinical Development
Alder BioPharmaceuticalsDirector Target Biology

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.